RxDoctor Payments Data

Jeffrey Rubin, MD

Neurology · West Palm Beach, FLNPI 1730280942

Payments from drug & device makers

$2,027in general payments, 2019–2025

Across 73 payments — averaging $27.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$529
  • UCB, Inc.$468
  • Biogen$219
  • Supernus Pharmaceuticals, Inc.$190
  • Genentech USA, Inc.$158
  • Novartis$141
  • plus $322 from 7 others

What the payments were for

  • Food & beverage$2,027100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,027 in reported general payments places this provider in the 45th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$33,945
Medicare patients
169
Services billed
296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5030$348,799
Kesimpta PenOfatumumab13$129,671
UbrelvyUbrogepant29$32,273
Lacosamide38$6,456
Levetiracetam101$5,668
Oxcarbazepine43$3,448
Carbidopa-LevodopaCarbidopa/Levodopa67$1,663
Carbamazepine ErCarbamazepine14$1,245
Duloxetine Hcl33$1,071
Divalproex Sodium ErDivalproex Sodium21$1,030
Donepezil Hcl78$937
Lamotrigine24$537
Propranolol Hcl ErPropranolol Hcl19$523
Baclofen11$509
Primidone25$499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$529$32,27329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,434 neurology providers in Florida.

Other neurology in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →